公司资料
Kyverna Therapeutics 股价、新闻与催化剂
- 股票代码:
- KYTX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
8.95 USD (+9.55%)
收盘价
最后更新: 2026年8月17日
480M USD
市值
股价为何变动
As of Aug 17, 2026, KYTX closed up 9.55% at $8.95. No new same-company headline was identified in the current news window.
公司概览
Autoimmune CAR T Company
Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases.
Miv-cel
Mivocabtagene autoleucel, or miv-cel, is a fully human CAR T therapy designed to produce deep B-cell depletion after a single administration.
Stiff Person Syndrome
The pivotal KYSA-8 study supports the first planned BLA for an autoimmune CAR T therapy in stiff person syndrome.
Broader Autoimmune Development
Kyverna is also advancing miv-cel in generalized myasthenia gravis and other autoimmune disorders.
未来催化剂
- Completion of the rolling miv-cel BLA submission in stiff person syndrome is expected in the fourth quarter of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。